A London semiconductor startup building chips designed for the human body has raised fresh money to move from validation to market. MintNeuro announced a $5 million investment round to drive its commercial scale-up, led by Odyssey Ventures with participation from 33East, JSK Investments and Alumni Ventures, alongside returning backers including Empirical Ventures and Jumpspace Ventures.
MintNeuro’s pitch is that device and therapy developers face a bad choice today: generic components that were never designed for the body, or years of expensive custom chip development. Its specialised chips aim to give neural-device makers — building implants and wearables — better performance than generic parts, with less risk, lower cost and a faster route to market than designing their own silicon.
The company will use the funding to grow its engineering and commercial teams, bring products to market, support customers adopting its chips, and strengthen its presence in the United States alongside its UK and European base.
“Neurotechnology is entering a phase where specialised hardware will determine how far, and how fast, the field can go,” said Professor Tim Denison, MintNeuro’s chair. Co-founder and CEO Dorian Haci said the funding moves the company “from technology validation to commercial scale-up, with more customer programmes, faster product launches and our chips in the hands of many more developers.”




